| 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01203 | 說明 | | 不適用 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 907,593,285 | | 0 | | 907,593,285 | | 增加 / 減少 (-) | | | | | | | | | | 本月底結存 | | | | 907,593,285 | | 0 | | 907,593,285 | 第 2 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 粵海廣南(集團)有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 不適用 FF301 第 1 頁 ...

Core Viewpoint - Guangnan Group (01203) reported a revenue of HKD 9.452 billion for the first three quarters, representing a year-on-year increase of 10%, while the profit attributable to shareholders was HKD 109 million, a decrease of 6% compared to the previous year [1] Financial Performance - Revenue for the first three quarters reached HKD 9.452 billion, marking a 10% year-on-year growth [1] - Profit attributable to shareholders was HKD 109 million, reflecting a 6% decline year-on-year [1]

Core Viewpoint - Guangnan Group (01203) reported a revenue of HKD 9.452 billion for the first three quarters, representing a year-on-year increase of 10% while the profit attributable to shareholders decreased by 6% to HKD 109 million [1] Financial Performance - Revenue for the first three quarters reached HKD 9.452 billion, marking a 10% increase compared to the previous year [1] - Profit attributable to shareholders was HKD 109 million, reflecting a 6% decrease year-on-year [1]

Core Insights - The company reported a consolidated revenue of HKD 9.452 billion for the first three quarters of 2025, representing a 10% increase compared to the same period last year [1] - The company's attributable profit decreased by 6% year-on-year to HKD 109 million [1] Segment Performance - The food biotechnology segment generated revenue of HKD 7.836 billion, an 11% increase year-on-year, but the segment profit (excluding share of associates) fell by 12% to HKD 138 million [1] - The company maintained its slaughtering operations in the Greater Bay Area, with a live pig slaughter volume of approximately 2.34 million heads, but faced a decline in operating profit due to intensified regional competition and price adjustments [1] - The market share for live pigs supplied to Hong Kong decreased to 48% from 49% year-on-year, leading to a reduction in profits from the live pig distribution business [1] - The company is expanding its food wholesale and retail operations in Hong Kong, currently operating 19 retail stores [1] - The performance of the joint venture in live pig breeding and sales slowed down due to falling pig prices in the third quarter, with the company's share of profits from associates amounting to HKD 18.91 million [1] - After accounting for the share of profits from associates, the segment profit for food biotechnology was HKD 157 million, a decrease of HKD 8.92 million or 5% year-on-year [1]

Financial Performance - For the first three quarters of 2025, the company's unaudited consolidated revenue was HKD 9.45 billion, an increase of 10% compared to HKD 8.58 billion in the same period last year[7]. - The unaudited consolidated profit attributable to shareholders for the same period was HKD 108.84 million, a decrease of 6% from HKD 115.82 million year-on-year[4]. - The food biotechnology segment generated revenue of HKD 7.84 billion, an increase of 11% year-on-year, but the segment profit (excluding share of profits from associates) decreased by 12% to HKD 138 million[8]. - The company maintained a total asset value of HKD 5.08 billion, reflecting a 3% increase from HKD 4.94 billion as of December 31, 2024[4]. - The equity attributable to shareholders rose by 4% to HKD 2.70 billion compared to HKD 2.59 billion at the end of 2024[4]. - The tinplate business produced and sold 240,000 tons of products, representing increases of 9% and 12% respectively, with segment profit rising by 81% to HKD 59.29 million[9]. - The company recorded a valuation gain of HKD 30,000 on investment properties, a significant improvement from a valuation loss of HKD 6.75 million in the previous year[10]. Market Challenges - The company continues to face challenges in the food biotechnology business due to fluctuations in pork prices and increased competition in the market[11]. - The overall market share for live pig distribution in Hong Kong decreased to 48%, down from 49% in the same period last year[8]. Retail Operations - The company is expanding its retail operations in Hong Kong, currently operating 19 retail stores[8].

Core Viewpoint - Guangnan Group (01203) announced significant changes in its board of directors effective from October 30, 2025, which may impact the company's governance structure and operational leadership [1] Group 1: Board Changes - Executive Director Yang Zhe has been reassigned from General Manager to Vice Chairman of the Board, while continuing to serve as Acting Chairman and Acting Chairman of the Nomination Committee [1] - Long Wenfang has been appointed as the Executive Director and General Manager of the company [1] - Zhou Hongji has resigned as Executive Director due to work adjustments but will continue in his roles as Chief Financial Officer, Company Secretary, and Authorized Representative under Listing Rule 3.05 [1]

2、 目的 2.1 協助董事會執行其職責，委員會的目的是檢討董事會的架構、人數 及組成，考慮董事候選人的技能、知識、經驗及獨立性後，向董事 會作出推薦出任董事人選的建議，確保本公司具備透明度的新董事 委任程序。 3、 委員會之成員 1 （於香港註冊成立的有限公司） （股份代號：01203） 提名委員會職責範圍 1、 組織 1.1 粵海廣南(集團)有限公司（「本公司」）之董事會（「董事會」）議決 設立一個董事會之委員會，名爲提名委員會（「委員會」）。 3.1 委員會的成員由董事會委任，其中一位必須為董事會主席，委員會 之成員數目由董事會不時決定但任何時間不能少於三名成員。委員 會的成員必須以獨立非執行董事佔大多數，而至少一名委員會成員 為不同性別。 3.2 委員會的主席由董事會的主席或獨立非執行董事擔任。委員會會議 的法定人數須爲兩位委員會之成員。 3.3 公司秘書應爲委員會之秘書。若委員會之主席否決的話，主席須提 名委員會之其中一位成員或其他合適人士爲秘書。 4、 會議 5、 職權 5.1 委員會可獲董事會之授權向本公司之任何高級職員及僱員索取其所 需的任何資料，而所有僱員已接獲指示應對委員會的任何要求予以 ...

Core Viewpoint - Guangnan Group (01203) announced significant changes in its board of directors effective from October 30, 2025, which may impact the company's governance structure and operational leadership [1] Group 1: Board Changes - Executive Director Yang Zhe has been reassigned from General Manager to Vice Chairman of the Board, while continuing to serve as Acting Chairman and Acting Chairman of the Nomination Committee [1] - Long Wenfang has been appointed as the new Executive Director and General Manager of the company [1] - Zhou Hongji has resigned as Executive Director due to work adjustments but will remain as Chief Financial Officer, Company Secretary, and Authorized Representative under Listing Rule 3.05 [1]

Core Viewpoint - Guangnan (Group) announced significant management changes effective from October 30, 2025, which include the appointment and reassignment of key executives [1] Group 1: Management Changes - Executive Director Yang Zhe has been reassigned from General Manager to Vice Chairman of the Board, while continuing to serve as Acting Chairman and Acting Chairman of the Nomination Committee [1] - Long Wenfang has been appointed as the Executive Director and General Manager of the company [1] - Zhou Hongji has resigned as Executive Director due to work adjustments but will continue to serve as Chief Financial Officer, Company Secretary, and Authorized Representative under Listing Rule 3.05 [1]

董事會名單、角色和職能 由 2025 年 10 月 30 日起，粵海廣南（集團）有限公司董事會共有 7 名董事。 每名董事的姓名、角色和職能載列如下： 1. 董事會 執行董事 審核委員會 楊哲( 代理主席及副主席 龍文芳( 總經理 ) 李嘉強 ( 於香港註冊成立的有限公司 ) (股份代號: 1203) 于會娟 李嘉強( 主席 ) 温引珩 Gerard Joseph McMahon 黃友嘉 楊哲( 代理主席 ) Gerard Joseph McMahon 黃友嘉 于會娟 香港，2025 年 10 月 30 日 非執行董事 薪酬委員會 獨立非執行董事 提名委員會 Gerard Joseph McMahon 李嘉強 黃友嘉 李嘉強 2. 董事委員會 ) Gerard Joseph McMahon ( 主席 ) 黃友嘉 ...